BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares are one of the big gainers in today’s market action. The biotech company’s trading volume is, as of 10:50 AM EST, over 12.5 million shares. That is quite a jump for a stock that has recently averaged under 2 million shares per day. BCRX closed Wednesday at $5.13. It gapped up to open this morning at $6.25 before hitting its inter-day high of $7.34 – a gain of 43%. BCRX continues to trade around $7.20 – at the higher end of today’s trading range.
The catalyst for the increased volumes and higher share prices was a report put out this morning by BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) concerning results from an interim analysis of the company’s Phase 2 APeX-1 clinical trial for hereditary angioedema (HAE). The Phase 2 trial is designed to measure the safety, tolerability, pharmacokinetics, and efficacy of BioCryst’s drug candidate BCX7353. The trial involves a three-part dosing regimen over 28 days. BCX7353 was developed as a preventative treatment to reduce the frequency of attacks in HAE patients.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Chief Executive Officer & President, Jon Stonehouse was quoted as claiming that the interim results support the company’s hypothesis that a daily dose of 125 mg of BCX7375 provides a high level of efficacy and tolerability when compared tto the 350 mg dose used in the first interim analysis. Overall, there were no serious adverse effects and the dosage was well tolerated over the entire subject group.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is a biotechnology company that develops small molecule drugs that are intended to block enzymes involved in rare diseases. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) first approved product was RAPIVAB, a peramivir injection. RAPIVAB is a viral neuraminidase inhibitor for influenza treatment and has been approved for sale in the USA, Japan, Canada, Taiwan, and Korea. RAPIVAB revenues will be well received by shareholders that have seen their BCRX shares suffer from dilutive effects and EPS losses for the past five years. EPS losses were (-$0.79) in 2012 followed by losses of (-$0.58), (-$0.68), (-$0.59), and (-$0.75) in 2016. On the other hand, in 2012 BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) had 49.74 million shares outstanding, a number which steadily grew and was reported at 73.70 million in 2016.
BCRX shares still have a ways to go before they breech their 52-week high of $9.25 or their 2015 high above $16. However, the trend is positive. In early 2016 BCRX shares briefly traded under $2. Since then ten of the next fifteen months have seen gains.
I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. All information, or data, is provided with no guarantees of accuracy.
About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.